Hims & Hers Health (NYSE:HIMS) COO Sells $441,850.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hims & Hers Health Trading Down 0.1%

NYSE HIMS opened at $35.44 on Friday. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The stock has a market cap of $8.20 billion, a P/E ratio of -393.79, a P/E/G ratio of 50.70 and a beta of 2.37. The stock’s fifty day moving average price is $26.74 and its 200-day moving average price is $26.64. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 earnings per share. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Flagship Harbor Advisors LLC bought a new stake in Hims & Hers Health in the 4th quarter worth approximately $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Bogart Wealth LLC lifted its holdings in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the period. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the 1st quarter worth $30,000. Finally, Greenline Wealth Management LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth $36,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HIMS. Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, June 8th. Citigroup raised their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Bank of America decreased their price objective on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday, May 26th. Barclays upped their price objective on Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $29.37.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.